Grant: CIHR - ICR / Cancer Research Society Partnership - Research Grants
University of Guelph
$62,500.00
Developing necroptosis for breast cancer immunotherapy
FY 2022-23
Summary
Stressed and dying cellssend several messagesthat educate immune cells whether a danger is apparent or not. We identified that killing tumors with after activating a necroptotic death createsimmune stimulation to provide strong anticancer immunity. By programming tumor cellsto die via a necroptotic pathway, the proposed study will evaluate the magnitude of immune response and aimsto identify the conditionsthat best alarm the immune system. Moreover, thisstudy will use programmable cancer-killing virusesto initiate immune stimulatory cell death thereby allowing the release of tumor cell contentsfor survey by the immune system.
Department
Program
CIHR - ICR / Cancer Research Society Partnership - Research Grants
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
488239
Name
Workenhe Samuel Tekeste
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Cancer Research Society Inc.; Cancer Research Society Inc.
Instname2
Cancer Research
Prcname2
Special Cases
Projecttitle
Developing necroptosis for breast cancer immunotherapy
Programtype2
Operating Grants
Orgnameinp2
University of Guelph
Cihramount2
$62,500
Cihrequipment2
$0
Programname2
CIHR - ICR / Cancer Research Society Partnership - Research Grants
Keyworddelim
Immunotherapy; Oncolytic Viruses & Immunotherapy
; Translational Research
Abstract
Stressed and dying cellssend several messagesthat educate immune cells whether a danger is apparent or not. We identified that killing tumors with after activating a necroptotic death createsimmune stimulation to provide strong anticancer immunity. By programming tumor cellsto die via a necroptotic pathway, the proposed study will evaluate the magnitude of immune response and aimsto identify the conditionsthat best alarm the immune system. Moreover, thisstudy will use programmable cancer-killing virusesto initiate immune stimulatory cell death thereby allowing the release of tumor cell contentsfor survey by the immune system.
Competitiondate
202302
Approvedterm2
1 yr 0 mth
Pinamesdelim
Workenhe, Samuel Tekeste
Approvedterm
1 an 0 mois
Cihrcontribution2
ICR~ $62,500~ $0~